Comments
Cipla on Thursday said that it has received the Establishment Inspection Report for its Goa plant from the United States Food and Drug Administration, indicating closure of the inspection. The inspection by the USFDA was conducted between January 21 and 28. Goa is home to Cipla’s largest plant as regards USFDA-compliant operations. The Goa unit contributes about 25 per cent of its total US sales in terms of filings, etc. Shares of Cipla may react positively to this development.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.